Cognoptix, a privately-held, diagnostics company with a breakthrough technology for the early detection of Alzheimer's disease (AD), announces that the company will present at the 13th Annual Biotech Showcase™ Digital Event, January 11-15, 2021. Read more >>
Cognoptix, a leading diagnostics company dedicated to the early detection of Alzheimer's disease (AD), announces two appointments to its senior management team. Dr. Carl H. Sadowsky, MD will serve as the company's new Chief Medical Officer (CMO) and Mike Kaswan, MBA will be Cognoptix's Chief Financial Officer (CFO). Read more >>
Cognoptix is a breakthrough diagnostics company developing an innovative office-based device-drug system for the early detection of Alzheimer's disease (AD). As another milestone of the Series R restart, recapitalization, and revitalization, the company named a new Board of Directors (BOD) formed under the leadership of Dr. Susanne Wilke, Ph.D., Cognoptix' new President and CEO. Read more >>
Cognoptix, a leading healthcare company for early-stage detection of Alzheimer's disease (AD), announces its co-founder, Lee Goldstein, M.D., Ph.D. has joined Cognoptix's Scientific Advisory Board, serving as Co-Chair, and the company's Board of Directors. Read more >>
Cognoptix, a leading diagnostics company dedicated to early detection of Alzheimer's disease (AD), announced today the formation of its new Scientific Advisory Board (SAB) with appointment of five world-class scientists and clinical researchers in AD. The SAB includes Jeffrey L. Cummings, MD, ScD; Lee E. Goldstein, MD, PhD; Philip Scheltens, MD, PhD; Martin R. Farlow, MD; and Carl H. Sadowsky, MD. Drs. Cummings and Goldstein will serve as SAB Clinical and Science Chairs, respectively. Read more >>
Cognoptix, a healthcare company developing the Sapphire II System, a breakthrough technology for early detection of Alzheimer's disease (AD), announces the closing of an over-subscribed Series R financing round. Cognoptix has undergone a complete revitalization over the past year. Read more >>
Cognoptix Inc CEO Susanne Wilke sat down with Proactive's Christine Corrado at the Biotech Showcase 2020 in San Francisco. The Concord, Massachusetts-based company develops non-invasive eye tests for the early diagnosis of Alzheimer's disease. Read more >>
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.